"West delivered adjusted EPS of $2.13 versus $1.68 consensus, a 27% beat, on net sales of $844.9 million against a $779 million estimate. Revenue grew 10.27% year over year with 15% organic growth."
"GLP-1 elastomers now represent 10% of total company revenue, with an additional 8% from GLP-1-related West Vantage contract manufacturing. The HVP Components segment grew 29.6% year over year to $409.3M."
"West is the entrenched supplier of injectable containment to the biologics and GLP-1 ecosystem, and the global Annex 1 regulatory framework upgrades further solidify its market position."
West Pharmaceutical Services experienced a 24.2% stock increase in the past month, driven by a strong Q1 2026 earnings report. The company reported adjusted EPS of $2.13, exceeding expectations, and net sales of $844.9 million. Revenue grew 10.27% year over year, with significant contributions from GLP-1 products. The company raised its full-year guidance, indicating continued momentum. West's structural advantages in the injectable containment market position it well for future growth, particularly in the biologics and GLP-1 sectors.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]